A ntibod y titres in im m unoglobulin preparations fo r intravenous use w ere tested against 24 dif ferent enterovirus serotypes and varied betw een 1 : 100 and 1 : 10,000 w ithin a single batch. Dif ferences up to 8-fold w ere found for hom olo gous titres betw een tw o different batches that w ere prepared 6 years apart. The lowest titre ob tain ed w as 1 : 40. T he observed d iffe re n ce s w ith in and between the two batches could not be explained by different incidence of serotypes of enteroviruses circulating at the tim e blood w as collected. Differences in titres of up to 18fold w ere observed w hen several strains of the sam e serotype w ere tested suggesting that intratypic variation influences antibody titres.
It is concluded that Im m unoglobulin prepara tions contain antibodies against m any en tero vi ruses, but that titres can be low and cannot be predicted from the incidence of any particular serotype circulating in the community. Because of intratypic variation, selection of a batch for specific treatm ent should be based on results obtained with the patient's own isolate, and not with a reference strain. J. 
INTRODUCTION
Enter o'viral infections are common, especially in neo nates and infants, and are usually asymptomatic or associated with nonspecific signs such as fever and flu like symptoms. However, such infections are occasion ally severe, or even fatal, causing myocarditis, hepati tis, meningitis, or meningoencephalitis. The host's con stitution and the virulence of the circulating virus are main determinants of disease severity [Melnick, 1996] , and antibodies are known to play a pivotal role in re solving infection. Thus, patients who suffer from hypoor agammaglobulinaemia and who are at risk of chronic meningoencephalitis can be given effective pro phylaxis with intravenous immunoglobulins (IVIG) [Galama, 1997; McKinney et al., 1987; Rotbart, 1995] . Once chronic meningoencephalitis becomes estab lished, high doses of immunoglobulin must be given by the IV route and sometimes intrathecally. Ideally, im munoglobulins with a high titre of specific antibody against the strain involved should be given, but the virus cannot always be cultured from cerebrospinal fluid [Galama, 1997; Rotbart, 1995] .
Neonates are also at risk of severe enteroviral dis ease [Cherry, 1995; Galama, 1997; Modlin, 1986] . They have subtle impairments of their host defenses and rely partly on maternally derived antibody for protec tion [Lewis and Wilson, 1996] . Indeed, there is some evidence that these antibodies can ameliorate infec tions [Modlin et al., 1981; Naginton et al., 1983] and mother-to-child transmission in the absence of specific antibody is considered to be a risk factor for severe disease [Galama, 1997; Modlin, 1986 ]. This provides the rationale for treating neonates with severe enteroviral infection with IVIG. However, the efficacy of this form of treatment has yet to be established [Abzug et al., 1995a; Johnston and Overall, 1989; Naginton et al., 1983] , which is difficult because treatment has to be started promptly before any information becomes available on the specific antibody levels [Abzug et al., 1995a; 1995b] .
Immunoglobulin is prepared from a pool of several thousand blood donations, as it is generally accepted that this will provide broad-spectrum coverage against the common nonpolio enteroviruses, of which 65 differ ent serotypes exist while minimising batch-to-batch variation. However, little is known about the specific antibody levels in these preparations. Therefore, we determined the amount of neutralizing antibody against 24 different serotypes of enterovirus in two Galama et al. batches of immunoglobulin that had been prepared 6 years apart and compared the antibody titres with the incidence of the different enteroviral serotypes that predominated in the Netherlands at the time the blood had been donated.
MATERIALS AND METHODS V iru ses
The nonpolio enteroviruses consist of 65 serotypes: 23 coxsackie A viruses (CAV), 6 coxsackie B viruses (CBV), 32 echoviruses (EV), and the enteroviruses (Ent), numbered 68-71 [Melnick, 1996] , The 20 sero types that occurred in the Netherlands during 1979-1994 with an incidence of >1% were selected, based on 14,471 isolates, of which 10465 (72%) were serotyped. In addition, 4 serotypes were included that were found with an incidence of <1%, but had been reported as causing severe disease [Cherry, 1995;  
Im m u n oglob u lin P rep a ra tio n s
Immunoglobulin preparations were kindly provided by the Central Laboratory of the Netherlands Red uross Blood Transfusion Service (CLB; Amsterdam, the Netherlands). Lot CLB-890628-675 had been col lected during 1986-1988, and lot CLB-950518-H61 during 1992-1994. Each batch contained the pooled Ig fractions derived from 3,000-5,000 donor units. Ig batches were considered to be representative for the whole country, since blood had been collected at Na tional Blood Centres and by additional campaigns con ducted in those regions lacking a blood donation centre. The preparations were freeze-dried and stored at 4°C. Immediately before use, they were reconstituted using distilled water in accordance with the manufacturer's instructions to a concentration of 6 g/dl.
A microneutralization assay was carried out in 96well plates seeded with 104 BGM cells per well in 0.2 ml of minimal essential medium (MEM), containing so dium bicarbonate, antibiotics and 2% fetal bovine se rum. The plates were incubated in a C 02 incubator at 37°C. Virus stocks were diluted to a concentration of 2,000 TCID50/inl. Reconstituted IG was diluted twofold from 1 : 4 to 1 : 2,048, or higher if needed in MEM containing HEPES buffer and antibiotics; 0.5 ml of Ig dilution was mixed with 0.5 ml of diluted virus suspen sion containing 1,000 TCID50. These mixtures were then incubated for 1 hr at 37°C and overnight at 4°C. Next day, 0.1 ml medium was removed from each well and replaced by 0.1 ml of the virus-Ig mixtures. Each dilution was tested in 8 wells. The final virus dose was checked by backtitration of 18 control samples without antibody and was estimated to be a mean 46 ± 10 TCID60/well (±2 SD). Neutralization reactions were read after 3 and 5 days and 50% endpoints were calcu lated according to the method of Reed and Muench [1938] , The precision of the neutralization assay was calculated for experiments using 6 different serotypes that were repeated on 7 different days; the mean dif ference in titre was found to be 1.69 ± 1.1 (±2 SD).
E p id em iology
The enteroviruses that had circulated in the commu nity during 1979™1994 were held in the registry of the Netherlands Working Group on Clinical Virology, which involves nearly all virus diagnostic laboratories in the Netherlands, reporting results on a monthly ba sis. The number of diagnostic laboratories increased from 8 in 1979 to 15 in 1991, and each has a regional function so that the whole country is covered. Most of the laboratories make use of the same virus isolation and typing procedures [Kapsenberg, 1988] , although the sensitivity of their techniques may have differed. Furthermore, asymptomatic and mild infections would have remained undetected since these cases are seldom referred for viral diagnosis. Therefore, the data re ported provides only a rough estimate of the actual incidence of individual viral infections in the commu nity.
RESULTS
Titres ranging from 1 : 40 to 1 : 10,720 were found against the various serotypes (Table I) and differences of up to 8-fold were noted between the two batqhes. There was no obvious correspondence between the lev els of any particular antibody and the incidence of in fection with that serotype in the Netherlands during 1979-1994. Comparison for two shorter periods of 5 years, starting shortly before, and ending after blood had been donated again failed to reveal any relation ship between the titres and the incidence of the various viral infections current at the time. Several strains of serotypes CBV2, CBV3, E9, and E20 were tested to investigate a possible effect of intratypic varia- [Cherry, 1995; Verboon et al., 1997] . Reciprocal values of titres, according to Reed and Muench. tion which was indeed observed and resulted in differ ences of up to 18-fold in titres, particularly for CBV3 (Table I) . DISCUSSION , 1994 ]. Ig has also been used for the treatment of chronic meningoencephalitis caused by an enterovirus, but this treatment has little success. Even when given intrathecally, IVIG is rarely helpful, and the disease is fatal in most patients. Therefore, the emphasis is on prophylaxis, although there are no data in the litera ture to indicate how this can be achieved optimally. The dosage of IVIG for maintenance treatment has been increased during the past decades. The present recommendation in the Netherlands is to maintain IgG concentrations in serum of >5 g/L [van der Meer and Zegers, 1994], but an efficacy study with a much higher dose is in progress.
Neutralization Assay Enterovirus Antibody in Immunoglobulin Preparations

IVIG is used frequently to protect patients with Ig deficiency against infections caused by common patho gens such as enteroviruses [van der Meer and Zeegers
Ig preparations for intravenous use contain the pooled Ig fractions from at least 1,000 blood donations. Some manufacturers prepare even larger pools, con taining 5=20,000 units. It is conceivable that a large pool size will provide a more constant quality, with antibody specificities that reflect the incidences of com- Period 1979 Period -1994 Period 1984 Period -1988 Period 1990 Period -1994 "Percentages of total numbers of enteroviruses, isolated in the Neth erlands during periods as indicated. Serotypes for which >4-fold difference in titres was observed between batch CLB-1989 and batch CLB-1995. mon infections in the general population. To check this, we compared antibody titres of IVIG with the inci dences of the corresponding enteroviruses in the Neth erlands. Antibodies were detected against all 24 sero types tested, but the titres for different serotypes var ied up to 200-fold. These 24 serotypes comprised those that frequently circulate but included some also that were less frequent but that have been reported to cause severe disease. Unexpectedly, there was no relation ship between antibody titres and the incidence of sero types. This is illustrated by low antibody titres found for EV11 and EV30, which were frequently isolated throughout the observation period, and by an inverse relationship between the incidence of EV19 infection at different times and antibody titres (Tables I, II ). This may be because the incidence data were based on clini cal isolates obtained from symptomatic infections that predominate in small children or because the serotypes that circulate among children differ from those among adults.
The differences between the two batches were only up to 8-fold, which is in the range reported by Dagan et al. [1983] . By contrast, Abzug et al. [1995a] found no variation in titres between 2 lots of IVIG derived from batches 10 times larger than those of the CLB. This suggests that a large pool size may reduce variability still further. On the other hand, these investigators provided no information on the interval between blood donations for the lots they tested. We also observed considerable variation in titres when several strains of 276 Gal am a et al.
the same serotype were tested, as did Abzug et al.
[1995aL Thus, the large pool size does not appear to compensate for intratypic variations, which might also explain why we failed to find any relationship between epidemiology and antibody titres, since prototype strains were employed, and only a few strains that had recently been isolated from patients.
Virus neutralization is a complex event in which dif ferent mechanisms are involved, such as aggregation of virus particles through antibody cross-linking, block ing of virus-receptor interaction, inhibition of cell pen etration, or inhibition of uncoating [Mosser et al,, 1989 ], Furthermore, it was recently shown that varia tion exists between individual virus isolates within the same serotype of coxsackie B virus in the capacity to bind to different cell surface receptors [Bergelson et al., 1997 ]. Studies such as ours cannot test for all possible mechanisms of intratypic variation and will conse quently have limitations. Hence, it remains the ideal to test IVIG preparations for antibody using the patient's own isolate despite the obvious difficulties involved. Nevertheless, our study has shown that antibody was at least present against all 24 serotypes employed. Some titres were low, but it is not known whether this might reduce therapeutic efficacy, nor does it give any indication of the titres that might be attained in a re cipient. This aspect of immunoglobulin treatment for enterovirus infections has received little attention so far and will be the subject of a future study in patients suffering from agammaglobulinemia.
